EGFR and bladder transitional cell carcinoma: Based on the large-scale transcriptomic data, Rebouissou et al. (2014) identified a subtype of BLCA presenting a basal-like phenotype, which was associated with shorter survival and presented an activation of the epidermal growth factor receptor (EGFR) pathway, implying basal-like BLCAs were sensitive to anti-EGFR therapy.